PharmaMar (MSE:PHM) presented new data on lurbinectedin during the World Conference on Lung Cancer (WCLC), which is taking place from 7th to 10th September in Barcelona.
- PharmaMar has presented data from a Phase Ib trial of lurbinectedin in combination with paclitaxel or irinotecan.
- Data from the Phase II trial with lurbinectedin as a single agent in a subset of 84 patients with a CTFI≥30 have also been presented.
- The mechanism of action of lurbinectedin will be discussed in an oral session on transcription as a target in the treatment of SCLC.
Madrid, September 9th, 2019. - PharmaMar (MSE:PHM) presented new data on lurbinectedin during the World Conference on Lung Cancer (WCLC), which is taking place from 7th to 10th September in Barcelona. The Conference, organized by the International Association for the Study of Lung Cancer (IASLC), brings together the world’s leading experts on this pathology and presents the latest advances in its treatment.
At this conference, PharmaMar presented two posters on lurbinectedin for the treatment of Small Cell Lung Cancer (SCLC).
The first of them evaluates new combinations with lurbinectedin for the treatment of this type of tumor. The poster entitled “Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Ib Trials (Abstract 1588)” shows the results of a Phase Ib trial in which combinations of lurbinectedin with paclitaxel or irinotecan were evaluated in patients with relapsed SCLC. Both combinations have shown similar activity and a predictable and manageable safety profile. The combination of lurbinectedin and irinotecan has shown encouraging activity in the third line treatment of patients. Also of interest, the combination of lurbinectedin and paclitaxel has shown higher activity in resistant patients (CTFI<90 days – patients for whom time from the last dose of first-line chemotherapy to the occurrence of progressive disease is less than 90 days).
These results warrant further evaluation of the combinations of lurbinectedin with paclitaxel or irinotecan. The expansion cohort of the irinotecan combination is already ongoing.
The second poster, entitled “Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose (Abstract 1710)” shows data from SCLC cohort of the Phase II Basket trial of lurbinectedin as a single agent, (presented in an oral session at the last ASCO Congress). Data are shown for the subset of 84 patients with a CTFI≥30 (time from the last dose of first-line chemotherapy to the occurrence of progressive disease is longer than or equal to 30 days). In this group of patients, the Overall Response Rate (ORR) was 40.5%. For the resistant patients with a CTFI of 30-89 days, the ORR was 29.2%, for whom no currently approved treatment exists. For the 60 patients that were sensitive (CTFI≥90 days; patients for whom time from the last dose of first-line chemotherapy to the occurrence of progressive disease is longer than or equal to 90 days), the ORR was 45%.
As for the safety of the compound in this group of patients, lurbinectedin has shown a safety profile that was acceptable and well tolerated. The most common treatment-related adverse effect has been neutropenia, and no unexpected toxicities have been observed.
During the Congress, Dr. Camilla L. Christensen, from Harvard University, will present in an oral session on transcription as a target in the treatment of SCLC, where, among others, the mechanism of action of lurbinectedin will be discussed. Lurbinectedin is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
About lurbinectedin
Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.
Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000
Investor Relations:
José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.
Phone: +34 914444500
